Genevant, a new company focusing on gene therapy

British Columbia, Canada-based Arbutus Biopharma and Switzerland-based Roivant Sciences have established Genevant Sciences. The new company will be based in Massachusetts and will aim to develop novel gene therapies (RNA) that will use Arbutus’ Lipid NanoParticle (LNP) technology to release active ingredients. Roivant will fund Genevant with $37.5m, intended to support Genevant to advance 5 to 10 product candidates into the clinic by 2020. Arbutus has licensed its LNP technology to Genevant and will be entitled to royalties on future sales.

(Source: Roivant)